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Abstract 
Background: A non-invasive method to grade the severity of steatohepatitis and liver 
fibrosis is magnetic resonance imaging (MRI) based corrected T1 (cT1). We aimed to 
identify genetic variants influencing liver cT1 and use genetics to understand mechanisms 
underlying liver fibroinflammatory disease and its link with other metabolic traits and 
diseases. 
Methods: First, we performed a genome-wide association study (GWAS) in 14,440 
Europeans in UK Biobank with liver cT1 measures. Second, we explored the effects of the 
cT1 variants on liver blood tests, and a range of metabolic traits and diseases. Third, we 
used Mendelian randomisation to test the causal effects of 24 predominantly metabolic traits 
on liver cT1 measures.  
Results: We identified six independent genetic variants associated with liver cT1 that 
reached GWAS significance threshold (p<5x10-8). Four of the variants (rs75935921 in 
SLC30A10, rs13107325 in SLC39A8, rs58542926 in TM6SF2, rs738409 in PNPLA3) were 
also associated with elevated transaminases and had variable effects on liver fat and other 
metabolic traits. Insulin resistance, type 2 diabetes, non-alcoholic fatty liver and BMI were 
causally associated with elevated cT1 whilst favourable adiposity (instrumented by variants 
associated with higher adiposity but lower risk of cardiometabolic disease and lower liver fat) 
was found to be protective.  
Conclusion: The association between two metal ion transporters and cT1 indicates an 
important new mechanism in steatohepatitis. Future studies are needed to determine 
whether interventions targeting the identified transporters might prevent liver disease in at 
risk individuals. 
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Lay summary:  
We estimated levels of liver inflammation and scarring based on magnetic resonance 
imaging of 14,440 UK Biobank participants. We performed a genetic study and identified 
variations in six genes associated with levels of liver inflammation and scarring. Participants 
with variations in four of these genes also had higher levels of markers of liver cell injury in 
blood samples, further validating their role in liver health. Two identified genes are involved 
in the transport of metal ions in our body. Further investigation of these variations may lead 
to better detection, assessment, and/or treatment of liver inflammation and scarring. 
  
6
Introduction 
Non-alcoholic and alcoholic fatty liver diseases are common in an era of a global obesity 
epidemic and concerning alcohol use.[1,2] They affect up to a third of the adult population 
worldwide and account for the vast majority of chronic liver diseases.[3] However, an important 
paradox in the history of liver fat accumulation exists; despite the large proportion of adults 
affected by simple steatosis (fatty liver), only a relatively small proportion (2.4 - 12.8%) will 
experience significant liver disease or liver related death.[4] 
It is important to identify which individuals are at risk of developing the more inflammatory 
phenotype, steatohepatitis, which is a condition characterised by lipotoxicity and histological 
necroinflammation and is considered to be the main pathophysiological driver of liver fibrosis 
and subsequent disease progression.[5] Steatohepatitis and fibrosis affect approximately one in 
ten middle-aged adults, and can lead to cirrhosis, hepatocellular carcinoma and death.[6] 
A promising, non-invasive measure of steatohepatitis and fibrosis severity is magnetic 
resonance imaging (MRI) based corrected T1 (cT1) (Figure 1A).[7–9] T1 relaxation time reflects 
extracellular fluid which is characteristic of fibrosis and inflammation. The presence of iron, 
which can be determined from T2* maps, has an opposing effect. Combining T2* and T1 values 
can correct for this opposing effect, from which cT1 (in milliseconds) is derived. Higher cT1 
values are associated with both histological liver inflammation and fibrosis, although their 
relative contributions to the score are still unknown.[9,10] cT1 has already been used as a non-
invasive outcome in randomised controlled trials for non-alcoholic steatohepatitis (NASH)[11] 
and is associated with liver disease outcomes.[8] 
Understanding the underlying genetic susceptibility of steatohepatitis and fibrosis may allow 
new insights on the main pathophysiological mechanisms contributing to chronic liver disease 
and help identify potential new drug targets. Genetic studies have so far been limited due to the 
phenotyping challenge. Liver biopsy is an invasive procedure with associated risks, significant 
sampling error and marked interobserver variance,[12] while routinely available liver blood tests 
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such as aminotransferases, despite being useful in the identification of important liver disease 
susceptibility loci, are overall poor predictors of liver disease severity.[13,14] 
Another challenging question is which metabolic traits cause steatohepatitis since treating 
causal factors can help prevent liver disease. Observational associations between 
steatohepatitis and other features of the metabolic syndrome might occur because they share 
common risk factors, rather than one causing the other. Mendelian randomisation (MR) is an 
established epidemiological approach that uses genetic studies to provide insight on 
causality.[15] MR uses genetic variants associated with an exposure (e.g. BMI, LDL cholesterol, 
insulin resistance) to assess their causal effect on an outcome of interest (e.g. cT1, 
steatohepatitis). Genetic markers of a risk factor are largely independent of confounders that 
may otherwise cause bias since genetic variants are randomly allocated before birth. 
Furthermore, the non-modifiable nature of genetic variants provides an analogy to randomised 
trials, in which exposure is allocated randomly and is non-modifiable by subsequent 
disease.[16] 
In this study, we aimed to (i) identify genetic variants influencing liver cT1 (ii) identify the effect 
of liver cT1 variants on other metabolic traits, (iii) investigate which metabolic traits are 
genetically correlated with cT1 measures and (iv) use MR to investigate whether 24 metabolic 
traits and conditions are causally associated with cT1. We performed the first genome-wide 
association study (GWAS) on MRI liver cT1 in 14,440 European individuals from UK Biobank. 
Finally, to investigate whether there are shared variants between liver cT1 and liver fat, we 
carried out a GWAS on MRI determined liver proton density fat fraction (PDFF) in the same 
cohort. 
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Methods 
UK Biobank participants  
UK Biobank is a prospective cohort study that consists of over 500,000 individuals aged 37–73 
years (99.5% were between 40 and 69 years of age) who were recruited between 2006 and 
2010 from across the U.K.[17] This research has been conducted using the data obtained via 
UK Biobank Access Application number 9914 and 31037. The UK Biobank has approval from 
the North West Multi-Centre Research Ethics Committee (ref: 11/NW/0382) and obtained 
written informed consent from all participants prior to the study.  
Imaging protocol and analysis 
Invitation to the UK Biobank imaging study is based only on proximity to one of the main 
imaging sites. Participants were invited and scanned at the UK Biobank Imaging Centre in 
Cheadle (UK) using a Siemens 1.5T Magnetom Aera as previously described.[18,19] Medical 
conditions were not taken into account except from those which would exclude the participant 
from being able to have an MRI (e.g. if they had an implanted defibrillator or metal implant).  
Characterisation of cT1 in the UK Biobank cohort, alongside normal values and inter and intra-
reader variability have previously been published.[18] Briefly, two sequences were used to 
acquire data: a Shortened Modified Look Locker Inversion (ShMOLLI) to quantify liver T1, and a 
multiecho-spoiled gradient-echo, to quantify liver iron and fat (PDFF). In both cases, data was 
acquired as a single transverse slice captured through the centre of the liver superior to the 
porta hepatis. Acquisition was performed in end-expiration breath-hold and without the aid of 
any contrast agent injection. The slice-based methodology has previously been shown to 
correlate well with histology and predict liver outcomes.[7,9] 
The MRI sequence is part of the LiverMultiScan© protocol from Perspectum Diagnostics (UK) 
which forms part of the UK Biobank abdominal imaging protocol.[18,20,21] The data was 
analysed by a team of trained analysts blinded to any participant variables, using 
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LiverMultiScan© Discover 4.0 software. This software creates T2*, cT1 and PDFF maps from the 
image data, and produces an automated delineation of the liver excluding its major vessels 
within the image slice using a deep learning approach which has previously been published;[22] 
The median value from this delineation on the T2* map is converted to an iron value,[23] which 
is used with the ShMOLLI data to derive the cT1 map.[24] All values reported in this work are 
the median, for each metric, of all usable voxels in the liver within the image slice. T1 relaxation 
time reflects extracellular fluid and is characteristic of fibrosis and inflammation. The presence of 
iron, which can be determined from T2* maps, has an opposing effect on the T1, and algorithms 
have been formed to correct for the resulting bias.[9] All processed data are available through 
application to UK Biobank. Figure 1A illustrates the 3 MRI scans with different levels of cT1 in 3 
participants.  
From an initial collection of 20386 imaging sessions (each of a unique individual), 691 did not 
have all necessary image data, 1354 were run with an early flawed protocol, 1717 did not 
correctly trigger the sequence, 126 had more than half of their liver excluded due to poor model 
fitting and motion artefacts, leaving 16498 for human quality control. 
From these a further 959 were removed through a combination of fat/water swaps, erroneous 
overcorrection of iron, misplacement of the image slice, segmentation failure, field artefacts, and 
cysts within the image slice preventing reasonable quantification of parenchyma leaving 15539 
participants. 
Genetic Data  
Protocols for the participant genotyping, data collection, and quality control have previously 
been described in detail.[17] Briefly, participants were genotyped using one of two purpose-
designed arrays (UK BiLEVE Axiom Array (n= 50,520) and UK Biobank Axiom Array (n = 
438,692)) with 95% marker overlap. We excluded individuals who were identified by UK 
Biobank as outliers based on either genotyping missingness rate or heterogeneity, or whose sex 
inferred from the genotypes did not match their self-reported sex. We removed individuals with a 
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missingness > 5% across variants which passed our quality control procedure. We used the 
latest release which included imputed data using two reference panels: a combined UK10K and 
1000 Genomes panel and the Haplotype Reference Consortium (HRC) panel. We limited our 
analysis to genetic variants with a minimum minor allele frequency (MAF) > 1% and imputation 
quality score (INFO) > 0.3.  
To define “white European” ancestry participants, we first used data from 1000 genomes 
samples to generate ancestry informative principal components (PCs). We then used these PCs 
in UK Biobank participants and employed K-means clustering to identify samples clustered with 
the three main 1000 genomes populations (European, African, and South Asian). Those 
clustered with the 1000 genomes’ “European” cluster were classified as having European 
ancestry.  
In total, after image analysis and quality control steps, liver cT1 and PDFF measures were 
available for 14,440 white European individuals who also had genetic data available and were 
classified as white European.  
Genome-wide association analysis  
We used BOLT-LMM v2.3.4 to conduct a linear mixed model GWAS which accounts for 
population structure and relatedness. We increased our power by including all related 
individuals of European descent (n = 14,440). The relatedness matrix was computed using 
common (MAF>5%) genotyped variants that passed quality control in all 106 batches and were 
present on both genotyping arrays. Prior to association testing, liver cT1 and PDFF were 
inverse-normal transformed. We used age, sex, centre and genotyping array as covariates in 
the model.  
Sensitivity Analyses 
We performed 6 sensitivity analyses (Supplementary Table 1). We carried out GWASs and 
adjusted for (i) BMI and (ii) alcohol units consumed. We derived alcohol units per day variable in 
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UK Biobank as previously suggested.[25] In summary, we considered 1.5 units for a glass of 
wine, 2.8 units for a pint of beer or cider and 1.5 units for other alcoholic drinks. We calculated 
one unit per week for individuals reported drinking alcohol at least once a week and one unit per 
month for individuals reporting less frequent drinking. We further adjusted for (iii) MRI 
determined liver fat and (iv) liver iron to rule out the confounding effects of these two traits in our 
image processing pipeline. Finally, we carried out GWASs in (v) males and (vi) females 
separately to detect sex-specific associations.  
Association of cT1 variants with liver biomarkers and metabolic traits and diseases.  
To further understand the role of each cT1 variants in the pathophysiology of liver disease, and 
also as a positive control, we tested the association between each variant and liver biomarkers 
in UK Biobank white European participants. The liver biomarkers include liver enzymes (ALT, 
AST, GGT, ALP in up to 378,821 individuals), MRI derived liver PDFF (n = 14,440), and MRI 
derived liver iron (to understand if the correction of T1 measures for liver iron content has 
caused any bias; n = 14,440). The protocols for the derivation of MRI PDFF and liver iron have 
previously been published.[20,21] To validate the associations with transaminases in a non-UK 
Biobank dataset, we looked up the effects of cT1 variants in an existing GWAS of ALT and AST 
levels in up to 61,089 individuals.[26] 
To understand the effect of cT1 variants on cardiometabolic traits and diseases, we tested their 
associations with 15 predominantly metabolic traits including BMI, HDL-cholesterol (HDL), LDL-
cholesterol (LDL), triglycerides, systolic blood pressure, diastolic blood pressure, type 2 
diabetes, and coronary artery disease in up to n = 379,308 white European UK Biobank 
participants.  
LD Score regression and cross-trait genetic correlation analysis 
We used LD Hub to conduct linkage disequilibrium (LD) score regression and heritability 
analysis. LD Hub is a centralized database of summary level GWAS for > 500 diseases 
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and traits from publicly available resources/consortia and uses a web interface that 
automates LD score regression, heritability and cross-trait genetic correlation analysis 
pipeline.[27] We ran heritability analysis as well as genetic correlation analysis across 
120 potentially relevant traits. SNP-based heritability (h2SNP) is the proportion of total 
variation in liver cT1 measures due to the additive genetic variation between individuals 
in our study population. 
Liver cirrhosis variants 
To investigate the effect of liver cirrhosis variants on cT1 measures, and also as a positive 
control, we used variants associated with all-cause cirrhosis including rs2642438 (in or near 
MARC1), rs72613567 (HSD17B13), rs58542926 (TM6SF2), rs738409 (PNPLA3), rs1800562 
(HFE), and rs28929474 (SERPINA).[28]  
Mendelian randomisation 
We investigated the potential causal associations between 24 predominantly metabolic traits on 
cT1 using two-sample Mendelian randomisation analysis.[29] We used the inverse variance 
weighted approach (IVW) as our main analysis, and MR-Egger and penalised weighted median 
as sensitivity analyses in order to detect unidentified pleiotropy of our genetic instruments. 
Genetic instruments were constructed by using the independent genome-wide significant 
genetic variants (R2 < 0.1) of the exposure of interest from previous GWASs. For more 
information on Mendelian Randomisation and genetic instrument selection please see the 
Supplementary Material. 
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Results 
The characteristics of liver cT1 cohort.  
In our discovery cohort, median age was 57 years (interquartile range (IQR) 50 - 62) for males 
and 55 years (IQR 48 - 60) for females. The median liver cT1 was 694 milliseconds (ms; IQR 
662 - 730) in males and 676ms (IQR: 647 - 710) in females (Supplementary Figure 1). 5.3% of 
males (299 / 5,595) and 2.6% of females (169 / 6,455) had values above 800ms, a threshold 
that has been set in current clinical trials as a cut-off for steatohepatitis,[30] and is under 
evaluation by the FDA and European Medicines Agency as a diagnostic enrichment biomarker 
for non-alcoholic steatohepatitis. Baseline characteristics were comparable to the rest of the UK 
Biobank cohort who did not participate in the imaging study except BMI, waist circumference 
and diabetes prevalence which were lower in both males and females in the liver cT1 cohort 
compared to the rest of UK Biobank (Table 1). Although invitation was not based on any 
medical information, MRI exclusion criteria (e.g. metal or electrical implants, surgery in six 
weeks prior to appointment, severe hearing or breathing problems) as well as the imaging site 
location (Cheadle, UK) may have contributed to a slightly healthier cohort.[21] 
Genetic variants in six loci show association with liver cT1. 
In our GWAS of liver cT1 in individuals of European ancestry variants in six independent loci 
(Table 2) reached genome wide significance. Genomic inflation was low (λGC = 1.006, 
Supplementary Figure 2). We observed the strongest association with a missense variant, 
rs13107325, located in an exon of SLC39A8 (Figure 1B). The minor allele (T; allele frequency 
7%) of rs13107325 was associated with 0.54 standard deviation (SD) increase in cT1 (p = 1.2 x 
10-133). The mean cT1 was 692ms in individuals with no risk allele, 727ms in heterozygotes, and 
772ms in risk allele homozygotes (Supplementary Figure 3).  
Other independent variants included an intronic variant (rs759359281-CA > C) in SLC30A10 (p 
= 2.8 x 10-8), a missense variant (rs111723834-G > A) in PCK2 (p = 3.0 x 10-11), a missense 
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variant (rs4820268-A > G) in TMPRSS6 (p = 1.6 x 10-9), and two known cirrhosis variants 
(rs58542926-A > G) in TM6SF2 (p = 1.4 x 10-8) and (rs738409-C > G) in PNPLA3 (p = 9.6 x 10-
13). The six variants together explained 5.38% of variation in cT1 measures in white European 
UK Biobank participants with SLC39A8 variant explaining most of this variation (3.95%) (Table 
2). We estimated the SNP-based heritability (h2SNP) of liver cT1 to be 20%. This is higher than 
the heritability estimated for conditions and traits such as coronary artery disease (7%),[31] 
eczema (7%),[32] body fat % (10%)[33] and transferrin (16%), but lower than non-alcoholic fatty 
liver disease (NAFLD) (22-34%).[34] 
We did not detect any sex-specific associations and the effects were similar between men and 
women (Supplementary Table 1). Sensitivity analyses that further controlled for alcohol units 
intake and BMI did not identify any additional signals and did not significantly change the effect 
size (Supplementary Table 1). Sensitivity analyses that controlled for liver PDFF removed the 
effects of rs58542926 in TM6SF2 and rs738409 in PNPLA3, suggesting that the effects of these 
variants on cT1 measures are mediated through liver fat accumulation (Supplementary Table 
1). The cT1 increasing allele (G) at TMPRSS6-rs4820268 is associated with lower plasma iron 
levels and lower liver iron.[21] The effect of this variant on cT1 may be due to its effect on liver 
iron concentration since iron has an opposing effect to T1 relaxation time. However, sensitivity 
analyses that controlled for liver iron only slightly attenuated its effect on cT1 (from beta = 
0.066, p = 2 x 10-9 to beta = 0.054, p = 7 x 10-7) suggesting that other mechanisms are involved 
and that this is a true signal.  
Genetic variants in four loci show association with liver MRI determined PDFF. 
In our GWAS of liver PDFF in 14,440 individuals of European ancestry missense variants in four 
independent loci reached genome wide significance (rs1260326-C > T in GCKR, p = 3.9 x 10 -8, 
rs58542926-C > T in TM6SF2, p = 6.3 x 10-37 , rs429358-C > T in APOE, p = 5.6 x 10-11, 
rs738409-C > G in PNPLA3, p = 5.4 x 10-66 (Supplementary Table 2, Supplementary Figure 
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4). Genomic inflation was low (λGC = 1.04). Two of the four variants (rs738409 in PNPLA3, 
rs58542926 in TM6SF2) were shared between PDFF and cT1 in our GWASs. 
Four of the cT1 variants are associated with higher levels of aminotransferases and 
demonstrate variable effects on metabolic traits and diseases. 
To validate these variants and further understand their role in other metabolic traits and 
diseases, we investigated their association with liver blood tests, MRI determined liver iron and 
liver PDFF, lipids, blood pressure, BMI and cardiometabolic disease outcomes (Figure 2, 
Supplementary Table 3). cT1-increasing alleles at four variants (in SLC30A10, SLC39A8, 
TM6SF2, and PNPLA3) were associated with higher ALT and AST (all with p-values < 2 x 10-5) 
and higher risk of type 2 diabetes (all with p < 0.002, except the SLC30A10 variant). None of 
cT1 variants were associated with cardiovascular disease risk, whilst their effects on other 
metabolic traits including lipids and blood pressure were variable (Figure 2). Among the novel 
identified and replicated variants (rs759359281 in SLC30A10, and rs13107325 in SLC39A8), 
only the latter was available in a non-UK Biobank cohort with available liver blood tests. The 
cT1-increasing allele in rs13107325 showed similar direction of effect on ALT (n = 46,316, beta 
= 0.01, p = 0.27) and AST (n = 39,015, beta = 0.014, p = 0.0005) levels in an independent 
cohort (Supplementary Table 4).[26] 
Liver cT1 measures correlate genetically with components of metabolic syndrome. 
We calculated genetic correlations using the GWAS summary statistics (120 predominantly 
metabolic traits/diseases) in LD score regression analysis (Figure 3, Supplementary Table 5). 
Measures of insulin resistance, triglycerides, VLDL, type 2 diabetes, coronary artery disease, 
body fat percentage, BMI and waist-to-hip ratio were genetically positively correlated with liver 
cT1 measures after correcting p-values for multiple testing (false discovery rate (FDR) < 0.05). 
The most genetically correlated traits were homeostatic model for insulin resistance (HOMA IR, 
rG= 0.53, P=0.0004) and mean diameter of VLDL particles (rG=0.52, P=0.0004), whereas the 
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strongest inverse correlation was seen with total cholesterol in very large HDL (rG=-0.62, 
P=0.04). 
Association of liver cirrhosis variants with liver cT1 
We investigated the effects of all-cause cirrhosis risk variants on cT1 values. Among six variants 
associated with all-cause cirrhosis in a recent GWAS of 5,770 cases and 572,850 controls [28], 
four variants (those in or near MARC1, HSD17B13, TM6SF2 and PNPLA3) demonstrated 
associations with cT1 (Table 3) where alleles associated with higher risk of liver cirrhosis were 
also associated with higher cT1. The HFE haemochromatosis risk allele (in rs1800562) was 
inversely associated with cT1, however this is to be expected since cT1 measures are corrected 
for liver iron content. Consistently, this association became remarkably attenuated (from beta = 
-0.11, p = 8 x 10-7 to beta = -0.055, p = 0.02) in our sensitivity analysis correcting for liver iron 
content. In the GWAS of all-cause cirrhosis, the effect of a1-antitrypsin risk variant (rs28929474 
in SERPINA1) was very weak (p = 0.01) and present only when a recessive model was carried 
out (Table 3).[28] We did not have any risk allele homozygotes in our liver cT1 cohort and 
therefore could not perform a recessive model of associations with cT1. 
Mendelian randomisation analysis provides genetic evidence that non-alcoholic fatty 
liver, insulin resistance and obesity causally elevate liver cT1.   
Demonstrating causality using observational studies can be challenging due to the presence of 
confounders such as other features of metabolic syndrome and behaviours including smoking 
and alcohol intake.[35] In UK Biobank, we detected a strong correlation between cT1 and BMI 
(r2: 0.36, p = 5 x 10-324) and also between cT1 and MRI determined liver fat PDFF (r2: 0.62, p = 5 
x 10-324), and a weak but significant inverse correlation with liver iron (r2: -0.069, p = 6.6 x 10-18), 
which is to be expected since cT1 measures were corrected for liver iron (Supplementary 
Figure 5). We used genetic methods (Mendelian randomisation, Figure 4) that are generally 
free of biases such as confounding and reverse causation to examine the potential causal effect 
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of metabolic traits on liver cT1. We found evidence of a causal association between insulin 
resistance (IVW p = 0.0001), non-alcoholic fatty liver (IVW P = 0.01), type 2 diabetes (IVW p = 
0.004), BMI (IVW p = 0.002) and higher cT1. We also found evidence for a protective role of 
favourable adiposity variants (variants associated with higher adiposity but lower risk of 
cardiometabolic diseases and lower ectopic fat)[36] and cT1 (IVW p = 0.01) (Supplementary 
Table 6). Our analyses were robust across a range of sensitivity analyses (Supplementary 
Table 6). 
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Discussion 
We identified associations between six independent genetic variants and MRI-based liver cT1, a 
non-invasive marker of liver inflammation and fibrosis, in 14,440 participants in UK Biobank. 
These include 5 missense variants (in SLC39A8, PCK2, TM6SF2, PNPLA3, and TMPRSS6) 
and one intronic variant (in SLC30A10). The cT1-increasing alleles in four genes (SLC39A8, 
SLC30A10, PNPLA3, and TM6SF2) were also associated with higher AST (n = 360,731) and 
higher ALT (n = 361,940) in UK Biobank and also in an independent GWAS of liver enzymes 
(except for SLC30A10 and TM6SF2 where data was not available).[26] SLC30A10 and 
SLC39A8 encode metal ion transporters and PNPLA3 and TM6SF2 are known genes 
associated with fatty liver and cirrhosis. 
cT1 is a continuous trait, and analysed as such in our GWAS in line with other continuous traits 
such as blood pressure, BMI and height.[37–39] In some earlier publications, cT1 was reported 
using the Liver Inflammation and Fibrosis (LIF) score (Supplementary Material). The LIF score 
is a tri-linear mapping of cT1 onto a continuous scale from 0 to 4 based on the association of 
cT1 with histological fibrosis[9]. LIF categories were defined as having no (LIF <1), mild (LIF 1–
1.99), moderate (LIF 2–2.99), or severe (LIF 3–4) liver disease.[8] The LIF cut-off of 1.4 had a 
sensitivity of 91% and a specificity of 52% for the diagnosis of NASH versus steatosis (AUROC 
= 0.80), and corresponds to a cT1 value of 780ms; a slightly higher cutoff of 800ms is used in 
clinical trials[30] and is under evaluation by the FDA and European Medicines Agency as a 
diagnostic enrichment biomarker for non-alcoholic steatohepatitis;[9,40] The LIF score is no 
longer used since the medical and MRI physics community is more familiar with T1 for the 
assessment of inflammation and fibrosis across all specialties including cardiology and 
neurology.[11,18,41–45] In this GWAS study, the cT1 values reported are standardised across 
the MRI scanner model and field strength and show very high repeatability and 
reproducibility.[46]  
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The missense variant (rs13107325-C > T) in SLC39A8 is predicted to be deleterious in both 
Polyphen-2 and SIFT, and is associated with lower expression of SLC39A8 in human liver.[47] 
SLC39A8 encodes ZIP8 which has important roles in inflammation and immunity, and is a 
negative regulator of the NF-kB pathway.[48] ZIP8 is a divalent cation importer capable of 
transporting zinc, manganese, iron, cadmium and selinate; the substitution of C for T allele 
impairs the cellular uptake of metals by this protein.[49] It is not known which metal is involved 
in liver pathogenicity but there is evidence that hepatic ZIP8 regulates manganese metabolism 
in the liver, a metal ion that is hepatotoxic at high levels.[50] Zinc and selenium also have 
important roles in liver cellular injury, oxidative stress and dysregulated inflammation; dietary 
supplementation of both has shown benefit in animal models of liver disease.[51,52]  
The pathogenic role of SLC39A8 in liver inflammation and fibrosis is supported by studies in 
mice which provide mechanistic evidence for the critical role of ZIP8 in liver disease. Liu et al 
[53] used two mouse models to study the function of SLC39A8 in the liver. In the first model, 
they studied the chronic effect of SLC39A8 knockdown. The SLC39A8(neo/neo) homozygous 
mice died before or immediately after birth. The SLC39A8(+/neo) heterozygous mice had 
moderate ZIP8 deficiency which led to disruption of normal hepatocellular architecture, necrosis, 
inflammation, fibrosis and development of liver tumours with histopathological features 
consistent with hepatocellular neoplasms.[53] In the second model, they studied liver specific 
SLC39A8 knockdown by adenovirus delivered shRNA and demonstrated that liver damage in 
the chronic model is not due to some extrahepatic process. Liver specific ZIP8 downregulation 
for seven days resulted in substantial hepatomegaly, inflammation, proliferation, oxidative 
stress, liver injury and cell death.[53]  
The intronic variant in SLC30A10, a gene which codes a predominantly manganese metal ion 
transporter, was also associated with elevated cT1 measures in our study, as well as elevated 
transaminases in UK Biobank. Manganese is an essential metal required for the adequate 
functioning of numerous enzymes, however it is toxic and induces cell death at elevated cellular 
levels.[54] Loss-of-function mutations in SLC30A10 have previously been associated with 
  
20
cirrhosis, higher manganese levels in liver biopsy samples and neurotoxicity including 
parkinsonian like movement disorders.[54,55] 
The association between cT1 increasing alleles at the two novel loci (SLC39A8 and SLC30A10) 
and higher ALT and AST adds supportive evidence for their pathogenic role in the liver. The 
missense variant in SLC39A8 has previously been shown to be associated with multiple traits 
including alcohol intake, BMI, schizophrenia, Crohn’s disease, lower brain grey matter volume 
and microbiome diversity;[38,56–58]  we show for the first time a further novel association with 
higher diabetes and triglyceride levels, whilst highlighting variable effects on cholesterol levels. 
The associations of both variants with cT1 were independent of BMI, alcohol intake, liver fat 
percentage and liver iron content in our sensitivity GWAS models. 
We identified a further two missense variants that were associated with cT1 but not with 
elevated transaminases; therefore, further research is required to validate these findings and 
explore their potential role in liver inflammation and fibrosis. The cT1-increasing allele in 
rs111723834 (missense variant in PCK2, also an intronic variant in NRL) was associated with 
lower transaminases, lower risk of type 2 diabetes, and lower triglycerides. PCK2 encodes a 
mitochondrial enzyme that catalyzes the conversion of oxaloacetate to phosphoenolpyruvate 
and has a key role in hepatic gluconeogenesis. Mitochondrial phosphoenolpyruvate 
carboxykinase deficiency (M-PEPCKD) is a rare autosomal recessive disorder resulting from 
impared gluconeogenesis, and clinical characteristics include hypotonia, hepatomegaly, failure 
to thrive, lactic acidosis and hypoglycaemia.[59] The missense variant in PCK2 is also an 
intronic variant in NRL, and it is unclear which gene is associated with elevated cT1 measures. 
NRL however encodes for neural retinal leucine zipper transcription factor that is specifically 
expressed in neuronal retina cells, making it an unlikely causal gene candidate for liver cT1. The 
cT1-increasing allele (rs4820268-A > G)  in TMPRSS6 has previously been reported to be 
associated with lower plasma iron levels and lower liver iron content.[21,60] It is also associated 
with a dysmetabolic profile including higher LDL cholesterol, higher cardiovascular disease risk 
and hypertension (Figure 2). Its effect on cT1 however remained significant even after 
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correcting for liver iron content in sensitivity analyses, making it unlikely that the association was 
secondary to bias resulting from iron correction when calculating cT1. Previous Mendelian 
randomisation studies have shown that higher circulating iron may be cardioprotective,[61] 
possibly through reduced circulating LDL-cholesterol and lower blood pressure.[62] The same 
mechanisms may explain why the allele associated with lower circulating iron levels is 
associated with higher cT1.  
Known NAFLD and cirrhosis risk alleles in PNPLA3 and TM6SF2 were also associated with 
both elevated cT1 and MRI derived PDFF in our cohort. These associations provide strong 
positive controls for our study and validate for the first time the association with MR determined 
liver PDFF. The risk alleles in these two genes were further associated with higher risk of type 2 
diabetes, but with lower serum triglycerides, LDL cholesterol, and lower risk for cardiovascular 
disease, as previously described.[63,64] In our GWAS on PDFF, alongside PNPLA3 and 
TM6SF2, we further identified variants in GCKR (another known NAFLD variant which we have 
replicated) and APOE (apolipoprotein E, a gene which encodes a major cholesterol 
carrier).[63,65] The APOE risk allele (T) for PDFF is associated with higher risk of diabetes, and 
lower risk of cardiovascular disease and LDL cholesterol in independent GWASs.[66] This data 
provide evidence that cT1 and PDFF phenotypes share some but not all aetiopathogenic 
mechanisms. 
We demonstrated that four of five variants associated with all-cause liver cirrhosis (in PNPLA3, 
TM6SF2, HSD17B13, and MARC1)[28] were also associated with liver cT1 with the first two 
reaching genome-wide significance. The paradoxical inverse association between the liver iron-
increasing allele in HFE may be due to overcorrection since cT1 measures are corrected for 
liver iron content and were inversely correlated in our cohort. Adjustment for liver iron content in 
our sensitivity analysis remarkably attenuated the association with cT1. SERPINA1 variant was 
associated with all-cause cirrhosis only in a recessive model.[28] We did not have any 
homozygotes in our liver cT1 cohort to detect a recessive model of association with cT1.  
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Identifying causal mechanisms to steatohepatitis is crucial since interventions targeting these 
modifiable exposures may prevent liver disease progression. Our Mendelian randomisation 
study investigated 24 possible metabolic traits that may cause steatohepatitis. We provide 
genetic evidence that insulin resistance, non-alcoholic fatty liver and higher BMI causally 
increase cT1. Recent genetic studies have further identified variants associated with higher BMI 
but lower risk of type 2 diabetes, hypertension and heart disease.[67] These “favourable 
adiposity” variants are also associated with higher subcutaneous-to-visceral adipose tissue ratio 
and may protect from disease through higher adipose storage capacity, by promoting lipid 
deposition in subcutaneous tissue rather than within the circulation and ectopic places. The 
inverse link between favourable adiposity and steatohepatitis provides supportive evidence for 
the protective effects of this phenotype on a variety of cardiometabolic diseases, underlying 
mechanisms of which can be further explored and point to future preventive and therapeutic 
strategies.  
Our study had a number of limitations. We did not have any independent cohort to replicate our 
findings. To overcome this limitation, we investigated associations between cT1 variants and 
ALT and AST levels both in UK Biobank and an independent GWAS of liver enzymes.[68] While 
MRI derived cT1 is clinically available and is used to assess the severity of steatohepatitis, this 
measure is still novel, and further research is needed to determine the relative contributions of 
inflammation and fibrosis to cT1.[10] Whilst it would be useful to have histological reference 
data for cT1, pathologist-interpreted liver biopsies do not lend themselves to large studies of this 
nature because of risk to patients and inter-rater variance in assessment of histology. This may 
be improved with advances in digitally processed histology to address variance and centralised 
collection of pathology for large consortia like the European LITMUS study. While cT1 has 
demonstrated excellent repeatability[42,46] and good correlation with fibro-inflammation and 
clinical outcomes,[7,9] other histological phenomena such as simple steatosis and ballooning 
have been shown to contribute to an increased T1 signal.[7] Only two of the six cT1 variants 
were associated with liver steatosis which highlights the complementarity of cT1 and liver fat 
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PDFF as biomarkers of liver status, and their potential to recognise different mechanisms 
predisposing to liver disease. 
Conclusion 
cT1 and PDFF phenotypes share some but not all aetiopathogenic mechanisms. We identified 
novel associations between an MRI derived measure of fibroinflammatory liver disease and 
variants in SLC30A10 and SLC39A8 that replicated with blood biomarkers of hepatocyte injury. 
These genes have a critical role of transporting heavy metal cofactors for a multitude of 
biological processes. Future studies may determine whether targeting SLC30A10 and SLC39A8 
are possible therapeutic options to prevent liver disease in at risk individuals. Our Mendelian 
randomisation study provides genetic evidence that addressing weight gain and insulin 
resistance are useful strategies in the prevention of steatohepatitis. 
Data availability  
Full data including individual cT1 and PDFF measures will be returned to UK Biobank and made 
publicly available via application (amsportal.ukbiobank.ac.uk).    
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Tables 
Table 1. Characteristics of UK Biobank participants in the imaging subset and the subset 
of participants who were not part of the imaging study. 
 
UK Biobank imaging subset UK Biobank non-imaging subset 
Characteristics Men Women Men Women 
No (%) 7,142 8,396 229,134 273,402 
Age  
(IQR) (years) 57 (50;62) 55 (48;60) 58 (50;64) 57 (50;63) 
Waist 
Circumference (IQR) 
(cm)* 94 (87;100) 79 (73;87) 96 (89;103) 83 (75;92) 
Townsend 
deprivation index 
(IQR) 
-2.78 
 (-3.98;0.82) 
-2.66  
(-3.90;-0.69) 
-2.12 
(-3.65;0.63) 
-2.14 
 (-3.63;0.49) 
Self reported 
diabetes (%)* 245 (3.43%) 116 (1.38%) 15,950 (7.0%) 9,794 (3.6%) 
Liver cT1  
(IQR) (ms) 694 (662;730) 676 (647;710) NA NA 
BMI 
(IQR) (kg/m2)* 26.6 (24.5;28.8) 25  (22.9;28) 27.3 (25;30.1) 26.1 (23.5;30) 
* BMI (Mann Whitney U test, p = 1 x 10-80), waist circumference (Mann Whitney U test, p = 1 x 10-100), diabetes 
prevalence (Pearson’s chi squared test, p = 1 x 10-27) were lower in the imaging subset compared to the rest of UK 
Biobank. Levels of significance for all tests: (p < 0.05).  
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Table 2. The association between six independent genetic variants and liver cT1. A linear 
mixed model was used for genetic associations (levels of significance: p < 5 x 10-8). 
SNP CHR BP EA OA EAF Gene 
Variant 
type 
Amino acid 
change 
BETA SE P-value 
Variance 
explained 
rs759359281 1 220100497 C CA 0.06 SLC30A10 Intron       0.137 0.026 2.8 x 10
-8
 0.23 
rs13107325 4 103188709 T C 0.07 SLC39A8 Missense  A391T 0.544 0.022 1.2 x 10
-133
 3.95 
rs111723834 14 24572932 A G 0.02 PCK2, NRL Missense  A561G  0.291 0.046 3.0 x 10
-11
 0.27 
rs58542926 19 19379549 T C 0.07 TM6SF2 
Missense, 
Intron 
  
I148M 0.124 0.022 1.4 x 10
-8
 0.22 
rs4820268 22 37469591 G A 0.46 TMPRSS6 Missense  V736A 0.066 0.012 1.6 x 10
-9
 0.2 
rs738409 22 44324727 G C 0.21 PNPLA3 Missense  E167K 0.095 0.014 9.6 x 10
-13
 0.9 
  
Effects are in standard deviations (SD). SE = Standard error; CHR:  = Chromosome; BP = Base pair; EA = Effect 
allele; OA = Other Allele; EAF = Effect allele frequency.   
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Table 3. Effects of all-cause cirrhosis risk alleles on liver cT1. * indicates recessive 
models were run for the previously published all cause cirrhosis GWAS; all other 
association analyses used additive models. Logistic regression was used for the genetic 
associations with cirrhosis; a linear mixed model was used for the genetic associations 
with cT1 (levels of significance: p < 5 x 10-8, suggestive p < 0.05) 
SNP CHR EA OA EAF BETA 
Cirrhosis 
P     
Cirrhosis 
BETA  
cT1 
SE     
cT1 
P cT1 Gene 
rs2642438 1 G A 0.297 0.12 8.7 x 10
-7 
0.036 0.0127 0.0049 MARC1 
rs72613567 4 T TA 0.722 0.16 4.5 x 10
-8
 0.030 0.0129 0.02 HSD17B13 
rs58542926 19 T C 0.927 0.35 9.7 x 10
-24
 0.124 0.0221 1.4 x 10
-8 
TM6SF2 
rs738409 22 G C 0.211 0.38 2.2 x 10
-67
 0.095 0.0141 9.6 x 10
-13
 PNPLA3 
rs1800562* 6 A G 0.925 1.16 1.3 x 10
-14
 -0.111 0.0223 8 x 10
-7
 HFE 
rs28929474* 14 T C 0.0186 0.29 0.01 -0.037 0.0430 0.47 SERPINA1 
 
CHR = Chromosome; EA = Effect allele; OA = Other Allele; EAF = Effect allele frequency; SE = Standard error; * = 
recessive models used for all cause cirrhosis analysis. Beta Cirrhosis is the effect on all-cause cirrhosis in log(Odds 
Ratio) and Beta cT1 is the effect on cT1 in standard deviation (SD). 
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Figure 1. GWAS of Liver cT1 in UK Biobank. 1A. Liver MRI scans of cT1. Three selected 
cases of liver MRI scans showing, from left to right, progressively elevated cT1 values (671ms, 
777ms, 917ms). 1B. Manhattan plot illustrating GWAS of liver cT1 measurements in 
14,440 UK Biobank individuals (~12 million imputed variants). The x-axis is the 
chromosomal position and y-axis is the significance of association for each variant in log10(p-
values). Grey line indicates genome-wide significance level. For the GWAS, a linear mixed 
model was used. Levels of significance: p < 5 x 10-8
. 
Figure 2. Forest plot of the associations of liver cT1 variants with liver and metabolic 
phenotypes. Effects are in standard deviations (SD) for continuous traits and log(OR) for 
disease outcomes per copy of the risk allele. ALT = Alanine transferase, AST = Aspartate 
transferase, GGT = gamma-glutamyl transferase, ALP = alkaline phosphatase, LDL_C = LDL 
cholesterol, HDL_C = HDL cholesterol, T2DM = Type 2 Diabetes, CAD = coronary artery 
disease. A linear mixed model was used for genetic associations. Levels of significance: p < 
0.05. 
Figure 3. LD regression analysis. Figure demonstrating the significant genetic correlations 
(rg) between cT1 and metabolic traits following correction for multiple testing (levels of 
significance: p false discovery rate < 0.05) among more than 120 traits. The colours correspond 
to significance of correlation (t-test); red: p < 1x10-8; orange: 1x10-6 < p < 1x10-5; blue: 1x10-5 < p 
< 1x10-4; green: 1x10-4 < p < 1x10-3; yellow: 0.001 < p < 0.01. Higher cT1 is genetically 
positively correlated with VLDL, type 2 diabetes, coronary artery disease, and inversely 
correlated with HDL. HOMA-IR = Homeostatic model assessment insulin resistance, HOMA-B = 
Homeostatic model assessment β cell function, VLDL = very large density lipoprotein, HDL = 
High density lipoprotein.  
Figure 4. Mendelian randomisation investigating the effect of 24 predominantly metabolic 
traits on liver cT1. We used two sample Mendelian randomisation analysis to investigate the 
causal effects of metabolic traits on liver cT1. For full results, including sensitivity analyses, 
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please see Supplementary Table 4. NAFLD = Non-alcoholic fatty liver disease, 2hrGlu = 2 
hour glucose tolerance test, WHR_BMI = Waist hip ratio adjusted for BMI. The inverse variance 
weighted test (IVW) was used as the main analysis. Levels of significance: p < 0.05. 
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Key Highlights:  
1) Variants in genes encoding for metal ion transporters (SLC30A10, SLC39A8) and in 
genes previously associated with liver fat (TM6SF2 and PNPLA3) are associated with 
both liver MRI-derived cT1 measures and transaminases in UK Biobank. 
2) cT1 is highly heritable, and shows positive genetic correlations with BMI, non-alcoholic 
fatty liver and VLDL, and inverse correlations with HDL. 
3) There is genetic evidence that insulin resistance, non-alcoholic fatty liver and higher BMI 
cause higher liver cT1, a proxy for steatohepatitis and liver fibrosis.
 
